AstraZeneca India stock rises on getting approval for Datverzo infusionAstraZeneca India stock rises on getting approval for Datverzo infusion

Introduction

Leading pharmaceutical company received regulatory approval to market Datverzo 100 mg infusion in India, targeting HR-positive, HER2-negative unresectable or metastatic breast cancer patients, expanding treatment options for advanced cases.

Also Read: Kaynes Technology shares jump after partnering with 2 Japanese firms to expand semiconductor manufacturing

Share price movement of AstraZeneca

On December 18, 2025, AstraZeneca Pharma India Ltd opened at ₹9,090.00, up 0.71% from its previous close of ₹9,025.80. The stock reached a high of ₹9,090.00 (0.71%) and a low of ₹8,950.00. By 3:11 PM, it traded at ₹9,086.00, a 0.67% increase, with a market cap of ₹22,715.00 crore.

AstraZeneca India Gets Approval for Datverzo

AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organization to import, sell, and distribute Datopotamab Deruxtecan 100 mg powder for concentrate for infusion in India.

Datopotamab Deruxtecan, marketed under the brand name Datverzo, is indicated for adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who received prior endocrine therapy and chemotherapy.

The approval allows AstraZeneca Pharma India to market Datverzo in India, subject to related statutory approvals, enabling access to treatment for patients with specified advanced breast cancer indications.

Stock performance of AstraZeneca for Period of 1 week, 6 months, and 1 year

AstraZeneca Pharma India Ltd delivered a 1.53% decline over the past week, it rose 1.53% in the past six months. The stock gained 39.0% over the past year.

Also Read: Jaykay Enterprises JV gets new LoA from Ircon International worth ₹162.25 Cr

Shareholding pattern of AstraZeneca

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	75.00%	75.00%	75.00%
FII	3%	3.00%	2.90%
DII	5.30%	4.60%	4.70%
Public	17%	17.40%	17.50%

About AstraZeneca

AstraZeneca Pharma India Ltd (NSE: ASTRAZEN) manufactures, distributes, and markets pharmaceutical products in India, providing innovative medicines across multiple therapeutic areas and contributing to healthcare solutions nationwide.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs